Evan Feinberg, a scientist and entrepreneur, has made significant strides in drug discovery and development at Genesis Therapeutics, a startup he founded and currently leads as CEO. Feinberg's research and expertise lies in applying deep learning methods to molecular property prediction, where he obtained his Ph.D. in Biophysics at Stanford University. Feinberg has served as a deep learning consultant for Merck, interned at Schrödinger, and held numerous research positions at both Yale University and Memorial Sloan-Kettering Cancer Center. Furthermore, he has found success in his entrepreneurial pursuits, having founded Keplr, a company specializing in biomedical device innovation.